The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical and radiometabolic correlatives of ddPCR liquid biopsy for BRAF V600 mutated melanoma.
 
Ronen Stoff
Consulting or Advisory Role - Pangaea Biotech
Speakers' Bureau - Merck Serono; MSD Oncology
 
Matthew Block
Research Funding - Alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Marker, Inc. (Inst); Merck (Inst); nference (Inst); Perspective Therapeutics (Inst); Pharmacyclics (Inst); Regeneron (Inst); Sorrento Therapeutics (Inst); TILT Biotherapeutics (Inst); Transgene (Inst); Viewpoint Molecular Targeting (Inst)
Patents, Royalties, Other Intellectual Property - Combinations of Dendritic Cell-Based Vaccines and Checkpoint Inhibitors, patent pending (Inst); Dendritic Cell-Based Vaccines and Uses Thereof, patent pending (Inst)
(OPTIONAL) Uncompensated Relationships - Sorrento Therapeutics; TILT Biotherapeutics; Viewpoint Molecular Targeting
 
Benjamin Kipp
No Relationships to Disclose
 
Geoffrey Johnson
Leadership - Green Clinic (I); Nucleus RadioPharma (Inst)
Stock and Other Ownership Interests - Perspective Therapeutics
Consulting or Advisory Role - AstraZeneca (Inst); Blue Earth Diagnostics (Inst); Curium Pharma (Inst); MedTrace (Inst); MorphImmune (Inst); Novartis (Inst); Siemens Healthineers (Inst); Viewpoint Molecular Targeting (Inst); Viewpoint Molecular Targeting (Inst); Z-Alpha (Inst)
Research Funding - Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); MedTrace (Inst); Novartis (Inst); Pfizer (Inst); Viewpoint Molecular Targeting (Inst); Viewpoint Molecular Targeting (Inst)
Patents, Royalties, Other Intellectual Property - Patents on Radiopharmaceuticals; Patents on Radiopharmaceuticals (Inst)
 
Yalda Nikanpour
No Relationships to Disclose
 
Gokce Bilgin
No Relationships to Disclose
 
Svetomir Markovic
Research Funding - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Nanoparticles (patents); Nanoparticles - immunoconjugates